U.S. markets closed
  • S&P Futures

    4,403.00
    +8.25 (+0.19%)
     
  • Dow Futures

    34,756.00
    +66.00 (+0.19%)
     
  • Nasdaq Futures

    15,099.50
    +26.00 (+0.17%)
     
  • Russell 2000 Futures

    2,198.10
    +6.40 (+0.29%)
     
  • Crude Oil

    68.37
    +0.22 (+0.32%)
     
  • Gold

    1,812.10
    -2.40 (-0.13%)
     
  • Silver

    25.38
    -0.08 (-0.32%)
     
  • EUR/USD

    1.1839
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    1.1840
    +0.0080 (+0.68%)
     
  • Vix

    17.97
    -0.07 (-0.39%)
     
  • GBP/USD

    1.3888
    +0.0003 (+0.02%)
     
  • USD/JPY

    109.6530
    +0.1850 (+0.17%)
     
  • BTC-USD

    39,799.30
    +1,357.82 (+3.53%)
     
  • CMC Crypto 200

    981.48
    +54.71 (+5.90%)
     
  • FTSE 100

    7,123.86
    +18.14 (+0.26%)
     
  • Nikkei 225

    27,631.16
    +47.08 (+0.17%)
     

Amicus Therapeutics to Present at the BTIG Virtual Biotechnology Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CRANBURY, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that members of the Amicus senior leadership team will participate in a fireside chat at the BTIG Virtual Biotechnology Conference on Tuesday, August 11, 2020 at 9:00 a.m. E.T.

A live audio webcast of the presentation can also be accessed via the investors section of the Amicus Therapeutics corporate website at https://ir.amicusrx.com/events-and-presentations.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.

CONTACT:

Investors:
Amicus Therapeutics
Andrew Faughnan
Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

FOLD–G